Banking of adipose- and cord tissue-derived stem cells: Technical and regulatory issues

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Stem cells are found in all multicellular organisms and are defined as cells that can differentiate into specialized mature cells as well as divide to produce more stem cells. Mesenchymal stem cells (MSC) were among the first stem cell types to be utilized for regenerative medicine. Although initially isolated from bone marrow, based on ease and costs of procurement, MSC derived from adipose tissue (AT-MSC) and umbilical cord tissue (CT-MSC) are now preferred stem cell sources for these applications. Both adipose tissues and cord tissue present unique problems for biobanking however, in that these are whole tissues, not cellular suspensions. Although the tissues could be processed to facilitate the biobanking process, by doing so additional regulatory issues arise that must be addressed. This review will discuss the technical issues associated with biobanking of these tissues, as well as regulatory concerns when banking of utilizing MSC derived from these sources in the clinic.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages147-154
Number of pages8
Volume951
DOIs
StatePublished - Nov 1 2016

Publication series

NameAdvances in Experimental Medicine and Biology
Volume951
ISSN (Print)00652598
ISSN (Electronic)22148019

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Adipose Tissue
Stem Cells
Tissue
Regenerative Medicine
Umbilical Cord
Suspensions
Bone Marrow
Costs and Cost Analysis
Bone

Keywords

  • Adipose tissue
  • Biobanking
  • Cord tissue
  • FDA
  • Regenerative medicine
  • Regulations
  • Stem cells

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Harris, D. T. (2016). Banking of adipose- and cord tissue-derived stem cells: Technical and regulatory issues. In Advances in Experimental Medicine and Biology (Vol. 951, pp. 147-154). (Advances in Experimental Medicine and Biology; Vol. 951). Springer New York LLC. https://doi.org/10.1007/978-3-319-45457-3_12

Banking of adipose- and cord tissue-derived stem cells : Technical and regulatory issues. / Harris, David T.

Advances in Experimental Medicine and Biology. Vol. 951 Springer New York LLC, 2016. p. 147-154 (Advances in Experimental Medicine and Biology; Vol. 951).

Research output: Chapter in Book/Report/Conference proceedingChapter

Harris, DT 2016, Banking of adipose- and cord tissue-derived stem cells: Technical and regulatory issues. in Advances in Experimental Medicine and Biology. vol. 951, Advances in Experimental Medicine and Biology, vol. 951, Springer New York LLC, pp. 147-154. https://doi.org/10.1007/978-3-319-45457-3_12
Harris DT. Banking of adipose- and cord tissue-derived stem cells: Technical and regulatory issues. In Advances in Experimental Medicine and Biology. Vol. 951. Springer New York LLC. 2016. p. 147-154. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-45457-3_12
Harris, David T. / Banking of adipose- and cord tissue-derived stem cells : Technical and regulatory issues. Advances in Experimental Medicine and Biology. Vol. 951 Springer New York LLC, 2016. pp. 147-154 (Advances in Experimental Medicine and Biology).
@inbook{ebb9f3d8365f42de9305fafd79d0a8b6,
title = "Banking of adipose- and cord tissue-derived stem cells: Technical and regulatory issues",
abstract = "Stem cells are found in all multicellular organisms and are defined as cells that can differentiate into specialized mature cells as well as divide to produce more stem cells. Mesenchymal stem cells (MSC) were among the first stem cell types to be utilized for regenerative medicine. Although initially isolated from bone marrow, based on ease and costs of procurement, MSC derived from adipose tissue (AT-MSC) and umbilical cord tissue (CT-MSC) are now preferred stem cell sources for these applications. Both adipose tissues and cord tissue present unique problems for biobanking however, in that these are whole tissues, not cellular suspensions. Although the tissues could be processed to facilitate the biobanking process, by doing so additional regulatory issues arise that must be addressed. This review will discuss the technical issues associated with biobanking of these tissues, as well as regulatory concerns when banking of utilizing MSC derived from these sources in the clinic.",
keywords = "Adipose tissue, Biobanking, Cord tissue, FDA, Regenerative medicine, Regulations, Stem cells",
author = "Harris, {David T.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/978-3-319-45457-3_12",
language = "English (US)",
volume = "951",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "147--154",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Banking of adipose- and cord tissue-derived stem cells

T2 - Technical and regulatory issues

AU - Harris, David T.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Stem cells are found in all multicellular organisms and are defined as cells that can differentiate into specialized mature cells as well as divide to produce more stem cells. Mesenchymal stem cells (MSC) were among the first stem cell types to be utilized for regenerative medicine. Although initially isolated from bone marrow, based on ease and costs of procurement, MSC derived from adipose tissue (AT-MSC) and umbilical cord tissue (CT-MSC) are now preferred stem cell sources for these applications. Both adipose tissues and cord tissue present unique problems for biobanking however, in that these are whole tissues, not cellular suspensions. Although the tissues could be processed to facilitate the biobanking process, by doing so additional regulatory issues arise that must be addressed. This review will discuss the technical issues associated with biobanking of these tissues, as well as regulatory concerns when banking of utilizing MSC derived from these sources in the clinic.

AB - Stem cells are found in all multicellular organisms and are defined as cells that can differentiate into specialized mature cells as well as divide to produce more stem cells. Mesenchymal stem cells (MSC) were among the first stem cell types to be utilized for regenerative medicine. Although initially isolated from bone marrow, based on ease and costs of procurement, MSC derived from adipose tissue (AT-MSC) and umbilical cord tissue (CT-MSC) are now preferred stem cell sources for these applications. Both adipose tissues and cord tissue present unique problems for biobanking however, in that these are whole tissues, not cellular suspensions. Although the tissues could be processed to facilitate the biobanking process, by doing so additional regulatory issues arise that must be addressed. This review will discuss the technical issues associated with biobanking of these tissues, as well as regulatory concerns when banking of utilizing MSC derived from these sources in the clinic.

KW - Adipose tissue

KW - Biobanking

KW - Cord tissue

KW - FDA

KW - Regenerative medicine

KW - Regulations

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84995480713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995480713&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-45457-3_12

DO - 10.1007/978-3-319-45457-3_12

M3 - Chapter

C2 - 27837561

AN - SCOPUS:84995480713

VL - 951

T3 - Advances in Experimental Medicine and Biology

SP - 147

EP - 154

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -